Accessibility Menu
Radiopharm Theranostics logo

Radiopharm Theranostics(NASDAQ) RADX

Market Cap$40.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-84%
5 YearN/A
1 Year-42%
1 Month-35%
$2.83
+1.07%
+0.03Today
After hours$2.80-$0.03 (-1.06%)
Radiopharm Theranostics last closing stock price
MetricPriceDate
Last closeUSD 2.802026-08-07
Radiopharm Theranostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.11%USD 3.152026-07-31
1 month-35.28%USD 4.332026-07-08
3 month-30%USD 4.002026-05-08
Year to date-46.36%USD 5.222025-12-31
1 year-42.27%USD 4.852025-08-07
Since inception-84.15%USD 17.672024-12-05

Radiopharm Theranostics Financials at a Glance

Market Cap

$40.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-$2.94

P/E Ratio

-0.95

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.83

Volume

10,393.8

Open

$2.77

Previous Close

$2.80

Daily Range

$2.77 - $2.94

52-Week Range

$2.62 - $16.25

Estimated Earnings Date

Sep 24, 2026

RADX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Radiopharm Theranostics

Radiopharm Theranostics Limited is an innovative biotechnology company based in Australia, focused on developing advanced radiopharmaceutical treatments. Established in 2021, the company aims to fill critical healthcare gaps through its diverse pipeline of products designed for diagnostic imaging and therapeutic interventions.

Products and Services
  • RAD 204 targets PD-L1 for non-small cell lung cancer
  • RAD 202 is aimed at HER2 for breast cancer and solid tumors
  • RAD 301 and RAD 302 focus on pancreatic ductal adenocarcinoma and other cancers
Growth Outlook
  • Strategic partnership with Lantheus Holdings accelerates clinical development
  • Pipeline includes multiple promising candidates for various cancers
  • Market demand for radiopharmaceuticals is expected to grow significantly
Financial Highlights
  • Recent quarterly revenue of 1,360,121 AUD, reflecting ongoing investment in R&D
  • Cash and cash equivalents of 34,481,156 AUD, providing operational stability
  • Current ratio of 3.01 indicates strong liquidity position
Radiopharm Theranostics Limited is positioned in a rapidly evolving sector, with a focus on addressing unmet medical needs through its innovative products. The company's strategic partnerships and robust pipeline suggest a commitment to advancing healthcare solutions. Recent financial data indicates a solid cash position, which supports ongoing research and development efforts. As the demand for effective cancer treatments continues to rise, Radiopharm Theranostics is well-placed to capitalize on emerging opportunities in the biotechnology landscape.
AI Generated • Jul 28, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Riccardo Canevari

Website

radiopharmtheranostics.com

Headquarters

Carlton, VIC 3053, AU

RADX Financials

Key Financial Metrics (TTM)

Gross Margin

172.70%

Operating Margin

-402.78%

Net Income Margin

-363.95%

Return on Equity

-93.08%

Return on Capital

-85.22%

Return on Assets

-49.29%

Earnings Yield

-1.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$40.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.46M

Volume

10.39K

Avg. Volume

66.37K

Financials (TTM)

Gross Profit

-A$1.23M

Operating Income

-A$30.54M

EBITDA

-A$29.21M

Operating Cash Flow

-A$51.51M

Capital Expenditure

A$4.49

Free Cash Flow

-A$51.51M

Cash & ST Invst.

A$34.48M

Total Debt

A$0.00

Radiopharm Theranostics Performance Analysis

Radiopharm Theranostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 196,671N/A
20242024-06-30AUD 196,107-0.3%
20252025-06-30AUD 2,353,1171099.9%
Radiopharm Theranostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q12024-09-30N/A
Q22024-12-31N/A
Q22025-12-31N/A
Radiopharm Theranostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -23.66N/A
20232023-06-30AUD -21.57-8.8%
20242024-06-30AUD -24.3913.1%
20252025-06-30AUD -3.43-86.0%
Radiopharm Theranostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q12024-09-30N/A
Q22024-12-31N/A
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

A$1.36M

N/A

Gross Profit

-A$1.23M

N/A

Gross Margin

-90.30%

N/A

Market Cap

$40.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.89M

N/A

Employees

14

N/A

Net Income

-A$26.47M

N/A

EBITDA

-A$29.21M

N/A

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

A$34.48M

+194.7%

Total Debt

A$0.00

N/A

Accounts Receivable

A$11.35M

+154.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-49.29%

N/A

Return on Invested Capital

-65.55%

N/A

Free Cash Flow

-A$22.26M

-429.9%

Operating Cash Flow

-A$22.26M

-429.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics, Inc.
$3.58+0.28%
QNRXQuoin Pharmaceuticals, Ltd.
$5.36+11.90%
BCLIBrainstorm Cell Therapeutics Inc.
$0.79+0.31%
ADXNAddex Therapeutics Ltd
$5.95+2.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About RADX

What is the current price of Radiopharm Theranostics?

Radiopharm Theranostics is trading at $2.80 per share.

What is the 52-week range for Radiopharm Theranostics?

Over the past 52 weeks, Radiopharm Theranostics has traded between $2.62 and $16.25.

How much debt does Radiopharm Theranostics have?

As of the most recent reporting period, Radiopharm Theranostics reported total debt of A$0.00.

How much cash does Radiopharm Theranostics have on hand?

Radiopharm Theranostics reported A$19.08M in cash and cash equivalents in its most recent financial results.

What is Radiopharm Theranostics’s dividend yield?

Radiopharm Theranostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services